IFN-alpha Mochida500, a synthetic form of injectable interferon alpha, is produced by Mochida Pharmaceuticals, and is available in Japan. It has not been approved for use in the United States, but is in phase II trials. The company is also developing a Mochida IFN-beta for hepatitis C treatment (J Gastroenterol 2001; 36:242–247).